Pan Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pan Ma has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Qiuling Shi
School of Public Health, Chongqing Medical University, Chongqing, People’s Republic of China
2 shared publications Chang Liu
Clinical Trial Institute, Peking University Shenzhen Hospital, Shenzhen, China
1 shared publication- Cheng Lei
Department of Thoracic Surgery, Sichuan Cancer Center, Chengdu, Sichuan, People’s Republic of China
1 shared publication Fang Liu
Department of Pharmacy, The First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China
1 shared publication- Hao Tian
Department of Breast and Thyroid Surgery, Southwest Hospital, The First Affiliated Hospital of Army Medical University, Chongqing, China
1 shared publication - Hongfan Yu
Department of Pharmacy, The First Affiliated Hospital of Army Medical University, Third Military Medical University, Chongqing, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Pain Research and Management
- Vol. 2025 (1) , 3783225
Establishing Pain Thresholds for Functional Recovery After Lung Cancer Surgery: A Mediation Analysis of the Surgery–Pain–Functioning Causal Pathway
Objective: Pain is one of the most common and long‐lasting symptoms after lung cancer surgery, potentially impairing physical functioning. This study aims to investigate to what extent pain mediates the association between the different surgical approaches (single‐port VATS versus multiport VATS or thoracotomy) and postoperative functional recovery after lung cancer surgery, with the goal of establishing clinically actionable pain score thresholds. Methods: In a prospective cohort study including 1381 patients, pain and functional status (activity limitation and walking difficulty) were assessed daily in hospital with the Perioperative Symptom Assessment for Lung Surgery (PSA‐Lung). The structural equation model (SEM) was used to investigate the mediation effect of pain in the surgery–pain–functioning pathway. The pain thresholds on postoperative day (POD) 1, 2, and 3 for optimal functional recovery were identified, corresponding to the cutoff points of pain categorization that demonstrated the largest indirect effects in the models. Results: The surgical approach had a significant indirect effect on activity limitation and walking difficulty through pain severity ( p < 0.001), with a standardized effect value of 0.039 and 0.037, respectively. According to the largest mediation effects of pain categories generated from the each day SEM, the optimal pain score cutoffs are 5 on POD1, 4 on POD2, and 3 on POD3, for both activity limitation and walking difficulty. Conclusion: Our study quantified the partial mediating effects of pain between surgical approaches and postoperative functional status in patients with lung cancer surgery. The mediation effect–based pain thresholds support precise strategies for postoperative functional rehabilitation, which is considered the major goal of enhanced recovery after surgery. Trial Registration: Chinese Clinical Trials Registry: ChiCTR2000033016
- 1 January 2025
- Published by Wiley in Pain Research and Management
- Vol. 2025 (1) , 3783225
Open AccessEstablishing Pain Thresholds for Functional Recovery After Lung Cancer Surgery: A Mediation Analysis of the Surgery–Pain–Functioning Causal Pathway
Objective: Pain is one of the most common and long‐lasting symptoms after lung cancer surgery, potentially impairing physical functioning. This study aims to investigate to what extent pain mediates the association between the different surgical approaches (single‐port VATS versus multiport VATS or thoracotomy) and postoperative functional recovery after lung cancer surgery, with the goal of establishing clinically actionable pain score thresholds. Methods: In a prospective cohort study including 1381 patients, pain and functional status (activity limitation and walking difficulty) were assessed daily in hospital with the Perioperative Symptom Assessment for Lung Surgery (PSA‐Lung). The structural equation model (SEM) was used to investigate the mediation effect of pain in the surgery–pain–functioning pathway. The pain thresholds on postoperative day (POD) 1, 2, and 3 for optimal functional recovery were identified, corresponding to the cutoff points of pain categorization that demonstrated the largest indirect effects in the models. Results: The surgical approach had a significant indirect effect on activity limitation and walking difficulty through pain severity ( p < 0.001), with a standardized effect value of 0.039 and 0.037, respectively. According to the largest mediation effects of pain categories generated from the each day SEM, the optimal pain score cutoffs are 5 on POD1, 4 on POD2, and 3 on POD3, for both activity limitation and walking difficulty. Conclusion: Our study quantified the partial mediating effects of pain between surgical approaches and postoperative functional status in patients with lung cancer surgery. The mediation effect–based pain thresholds support precise strategies for postoperative functional rehabilitation, which is considered the major goal of enhanced recovery after surgery. Trial Registration: Chinese Clinical Trials Registry: ChiCTR2000033016
- 20 April 2023
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 22 (8) , 685-696
High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database
T-DM1 and T-DXd are two promising antibody-drug conjugates for treating advanced HER2-positive breast cancer and HER2-mutated lung cancer. Understanding the differences in the adverse events (AEs) ...
- 20 April 2023
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 22 (8) , 685-696
High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database
T-DM1 and T-DXd are two promising antibody-drug conjugates for treating advanced HER2-positive breast cancer and HER2-mutated lung cancer. Understanding the differences in the adverse events (AEs) ...
- Open Access
- 21 March 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 33, 120-129
Pharmacokinetic/pharmacodynamic comparison between generic and brand-name levofloxacin based on Monte Carlo simulation
- 21 March 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 33, 120-129
Open AccessPharmacokinetic/pharmacodynamic comparison between generic and brand-name levofloxacin based on Monte Carlo simulation